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Abstract
Background: Corticotropin-releasing factor (CRF) is typically considered to mediate aversive
aspects of stress, fear and anxiety. However, CRF release in the brain is also elicited by natural
rewards and incentive cues, raising the possibility that some CRF systems in the brain mediate an
independent function of positive incentive motivation, such as amplifying incentive salience. Here
we asked whether activation of a limbic CRF subsystem magnifies the increase in positive
motivation for reward elicited by incentive cues previously associated with that reward, in a way
that might exacerbate cue-triggered binge pursuit of food or other incentives? We assessed the
impact of CRF microinjections into the medial shell of nucleus accumbens using a pure incentive
version of Pavlovian-Instrumental transfer, a measure specifically sensitive to the incentive salience
of reward cues (which it separates from influences of aversive stress, stress reduction, frustration
and other traditional explanations for stress-increased behavior). Rats were first trained to press
one of two levers to obtain sucrose pellets, and then separately conditioned to associate a
Pavlovian cue with free sucrose pellets. On test days, rats received microinjections of vehicle, CRF
(250 or 500 ng/0.2 µl) or amphetamine (20 µg/0.2 µl). Lever pressing was assessed in the presence
or absence of the Pavlovian cues during a half-hour test.
Results: Microinjections of the highest dose of CRF (500 ng) or amphetamine (20 µg) selectively
enhanced the ability of Pavlovian reward cues to trigger phasic peaks of increased instrumental
performance for a sucrose reward, each peak lasting a minute or so before decaying after the cue.
Lever pressing was not enhanced by CRF microinjections in the baseline absence of the Pavlovian
cue or during the presentation without a cue, showing that the CRF enhancement could not be
explained as a result of generalized motor arousal, frustration or stress, or by persistent attempts
to ameliorate aversive states.
Conclusion: We conclude that CRF in nucleus accumbens shell amplifies positive motivation for
cued rewards, in particular by magnifying incentive salience that is attributed to Pavlovian cues
previously associated with those rewards. CRF-induced magnification of incentive salience provides
a novel explanation as to why stress may produce cue-triggered bursts of binge eating, drug
addiction relapse, or other excessive pursuits of rewards.
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Background
Corticotropin-releasing factor (CRF) is involved in medi-
ating the physiological and behavioral responses to stress
[1-5]. Beyond activating aversive behaviors, stress also
increases some appetitive behaviors. For example, food
intake and relapse into drug-taking in models of addiction
are both increased by natural CRF-releasing stressors [6-
11]. Such appetitive behaviors have often been viewed as
attempts to reduce or avoid unpleasant stress or as over-
flow from general motor arousal or frustration ([12-14]
but see [8-11]).
However, despite the traditional association of CRF with
aversive stress, some CRF brain systems also are activated
by positive rewards, even in the absence of conventional
stressors. For example, CRF release is increased in the cen-
tral nucleus of the amygdala by spontaneous food inges-
tion [10,15] and in prefrontal cortex by presentation of
Pavlovian cues associated with food reward [10]. Simi-
larly, sucrose ingestion normalizes CRF levels in hypotha-
lamus and amygdala in adrenalectomized rats [16]. In
addition, CRF has also been suggested to play an impor-
tant role in drug reward. For example, cocaine administra-
tion also activates CRF expression in CRH-producing
neurons in hypothalamus and amygdala [13] and CRF
given intracerebroventricularly (ICV) or into the ventrola-
teral BNST can induce reinstatement of drug self-adminis-
tration behavior in the absence of external stressors
(though this last could reflect attempts to escape aversive
CRF effects) [17].
Reward activation of CRF raises the possibility at least that
some brain CRF/glucocorticoid systems may participate
in positively valenced processes of incentive motivation
for reward. One candidate for positive motivation is the
attribution of incentive salience to conditioned stimuli
that predict rewards, magnification of which causes cue-
triggered phasic peaks of increased incentive motivation
for associated rewards. Incentive salience (i.e., cue-trig-
gered 'wanting' for a reward, but not necessarily 'liking' for
the same reward) has been shown to depend in part on
ascending dopamine projections to nucleus accumbens
[8-11]. Other neurochemical signals converging on the
nucleus accumbens from mesocorticolimbic circuits
could play roles in enhancing incentive salience too,
either directly or by via dopamine modulation [18-20].
Does a CRF subsystem in nucleus accumbens participate
in magnifying the incentive salience of cues previously
associated with reward? If so, that provides a novel expla-
nation for why stress sometimes potentiates appetitive
motivated behavior, especially when reward cues are
encountered. An incentive salience contribution would
serve as alternative or supplement to traditional explana-
tions such as escape from aversive states (i.e., anxiety, irri-
tability, dysphoria) or general arousal [12,13,21]. An
incentive-salience mechanism could also be relevant to
understanding relationships between stress and neural
sensitization in causing drug abuse, especially cue-trig-
gered relapse into addiction [22].
Here we tested the specific hypothesis that elevated CRF
neurotransmission in nucleus accumbens shell enhances
the incentive salience of cues that have been associated
with sucrose reward, and so magnifies 'wanting' for
sucrose. Nucleus accumbens contains levels of CRF recep-
tors that are comparable to those in amygdala [23-25].
The medial shell of nucleus accumbens also contains sub-
stantial distributions of CRF-immunoreactive and fibers,
which might arise in part from hypothalamic CRF systems
linked to stress, as well as cell bodies (particularly in its
caudal half, and thus we focused on caudal shell here)
[26]. Whether CRF acts directly on nucleus accumbens cir-
cuits in ways comparable to dopamine, or interacts with
dopamine release in nucleus accumbens, CRF release in
nucleus accumbens might facilitate incentive salience
mechanisms [27-31]. Taken together with previous find-
ings regarding the importance of nucleus accumbens in
incentive salience amplifications by amphetamine and
sensitization, it seems likely that if stress does modulate
incentive salience via CRF mechanisms it might do so here
in medial shell [1-5,30,31].
To selectively measure the enhancement of incentive sali-
ence by CRF, we used a pure incentive version of the Pav-
lovian-Instrumental transfer paradigm. This procedure
measures the intensity of peaks of incentive motivation
that are triggered by reward cues (a phenomenon that has
been called cue-triggered 'wanting'). It excludes non-
incentive explanations related to stress or stress reduction
as well as other alternative explanations for increased
behavior (e.g., primary instrumental response reinforce-
ment, secondary response reinforcement, discriminative
stimulus occasion setting, general stress/frustration drive,
Pavlovian S-R habits) [29-37]. In short, features of the
pure incentive Pavlovian-Instrumental transfer (PIT) pro-
cedure allow isolation of incentive salience enhancement
by CRF from other stress-related mechanisms as explana-
tion for magnified, sudden and intense cue-triggered
peaks in incentive motivation for reward.
Our results suggest that activation of CRF systems in the
medial accumbens shell can indeed enhance incentive
salience attributed to reward cues. Incentive salience,
amplified by CRF in nucleus accumbens, provides a new
explanation of why stressors sometimes cause increased
pursuit of rewards, especially at moments when stressed
individuals encounter cues that were previously associ-
ated with those rewards.BMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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Results
CRF and amphetamine in nucleus accumbens increase 
cue-triggered lever pressing associated with sucrose reward
CRF (high dose 500 ng/0.2 µl; low dose 250 ng/0.2 µl)
and amphetamine (20 µg/0.2 µl) microinjections were
located in the region of medial shell of nucleus
accumbens that contains highest CRF levels (Figure 1; Fig-
ure 2). CRF and amphetamine each dramatically and sim-
ilarly increased cue triggered incentive motivation to
obtain reward (Three-way ANOVA (drug × cue presence ×
lever), F3,159 = 5.57; p < 0.05, main effect of drug). Both
CRF and amphetamine comparably increased phasic CS+-
triggered peaks of increased pressing on the lever that pre-
viously had been associated with sucrose reward com-
pared to vehicle, but did not increase lever pressing at
other times (i.e., during CS- or in the absence of any CS)
(Two-way ANOVA (drug × cue presence), F3,79 = 4.21; p <
0.05, significant interaction) (Figure 3).
Post-hoc comparisons indicated that CRF enhancement of
cue-triggered peaks of lever pressing was exclusively due
to the highest dose of CRF (500 ng; Bonferroni, p < 0.05).
Specifically, 500 ng CRF microinjections tripled the
amplitude of phasic peaks in pressing on the sucrose-asso-
ciated lever during the 30-sec CS+ tone or clicker and in
the 30-sec period immediately after it, compared to the
same lever after vehicle microinjections (Figure 3), but
not during other periods. An equivalent tripling of cue-
triggered peaks in lever pressing was also produced by
amphetamine (20 µg) microinjections at the same sites
(Bonferroni, p < 0.05) (Figure 3), used as a standard here
for enhanced cue-triggered 'wanting', and confirming pre-
vious results [30,31]. By contrast, the low dose of CRF
(250 ng) failed to significantly enhance active lever press-
ing over vehicle despite the possibility of a slight trend
(Bonferroni, p = 0.42, n.s), and by itself the 30-sec CS+
elicited merely a modest rise of only 50% over pre-cue
baseline in lever pressing after vehicle microinjections,
which was less than half the maximum drug-enhanced
levels.
Associative cue specificity: CS+ vs baseline
In order to rule out motor arousal and general frustration
effects of CRF as explanations of increased peaks in incen-
tive motivation, it is crucial that enhancement not also
apply to the plateaus of lever-pressing during periods
between cue-triggered peaks. Motor arousal and aversive
effects can be caused by intracerebral microinjections CRF
[38-40]. However, motor arousal and frustration effects of
CRF would be expected to remain relatively constant over
a 30 min test, or at least last longer than the minute or so
impact of a cue. Thus if motor arousal or aversive states
Fos plumes Figure 1
Fos plumes. Coronal sections showing point sample positions used to identify local Fos plumes around microinjection site. A. 
Vehicle microinjection produces merely low elevation of Fos compared to normal virgin tissue. Radial arms extending from 
center show sampling points for Fos measurement (125 µm × 125 µm blocks; 5× magnification). B. CRF microinjection induces 
intense elevation over normal tissue levels (depicted by color: 10× elevation over normal denoted by yellow, 5× = dark orange; 
2× = light orange). CRF also causes elevation compared to vehicle microinjection levels at equivalent points (depicted by dot-
ted lines; 3× relative increase over vehicle-levels denoted by thick dotted line, 5× = thin dotted line; upper right; plume from 
CRF 500 ng dose in 0.2 µl microinjection volume).
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Fos plume maps of CRF (500 ng) amplification of cue-triggered increases in lever pressing Figure 2
Fos plume maps of CRF (500 ng) amplification of cue-triggered increases in lever pressing. Fos plume maps of 
functional localization: CRF effects on cue-triggered incentive salience. Sagittal (A), horizontal (B), and coronal maps (C) show 
each Fos plume as colored symbol in medial shell of nucleus accumbens. Color depicts magnification effect of CRF (500 ng) 
microinjection at that site on peaks of lever pressing triggered by a 30 sec auditory CS+ previously associated with sucrose 
reward (within-subject percentage elevation of CRF versus vehicle in the same rat; 100%=vehicle). Size of central symbol 
depicts radius of intense Fos elevation; size of surrounding halos depict outer radius of moderate Fos elevation. For the sagittal 
map, bilateral accumbens sites from left and right sides of each rat brain are collapsed together into one combined sagittal map 
of accumbens for simplicity. Maps adapted from Paxinos and Watson [46].
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were the explanation for elevated instrumental behavior
here, lever pressing during baseline periods in between
auditory stimuli should have been elevated too – not only
when a CS+ was present. However, neither CRF (500 or
250 ng) nor amphetamine (20 µg) produced detectable
increases in baseline instrumental responding during no-
stimulus baseline periods (One-way ANOVA (drug), F3,39
= 0.3, p = 0.8, n.s.). Baseline instrumental responding in
the absence of any CS (i.e., pre-cue periods) was never
increased by any microinjection (even when it increased
lever pressing in response to the CS+). This dissociation
between enhanced cue-triggered incentive motivation
during CS+ versus unchanged baseline responding was
separately confirmed in a two-way ANOVA by a signifi-
cant interaction between the presence/absence of CS+ and
administration of either CRF (drug × cue presence interac-
tion, F2,119 = 5.23, p < 0.05) or amphetamine (F1,79 = 4.25,
p < 0.05) (Figure 3).
Associative cue specificity: CS+ vs. CS-
Similarly, the CS+ (tone or click) was the only condi-
tioned stimulus that ever significantly increased lever
pressing on the sucrose associated lever (Three-way
ANOVA (cue type × drug × lever), F1,119 = 10.40, p < 0.001,
main effect of cue type; Figure 3). The control CS- (a dif-
ferent auditory stimulus that did not predict sucrose
reward) failed to increase lever pressing over the baseline
pre-cue period in any drug condition (Figure 3). That
selective pattern of only-CS+ enhancement is required by
the hypothesis of incentive salience magnification, which
posits that enhanced incentive salience is attributed spe-
cifically to stimuli previously associated with reward.
A useful way of further assessing the associative specificity
of CS+ effects versus CS- effects on Pavlovian-Instrumen-
tal transfer effects is to calculate transfer scores between
them. A transfer score directly contrasts pressing during
Enhancement of incentive motivation by CRF Figure 3
Enhancement of incentive motivation by CRF. Effects on cue-triggered lever pressing during extinction test caused by 
CRF (250 and 500 ng) and amphetamine (20 µg) microinjections in the caudal medial accumbens shell. A. Lines show pressing 
in the presence of the CS+ (previously associated with sucrose- red circles); and CS- (never associated with sucrose- blue cir-
cles); and pre-CS+ baseline period (no-stimulus 30 sec period immediately prior to CS+ stimulus); and pre-CS- baseline period 
(30 sec immediately prior to CS- stimulus). The left panel depicts lever pressing on the control lever that had previously pro-
duced instrumental sucrose reward during training (but not during extinction test). The right panel depicts lever pressing on 
the control lever that was never had produced reward. Both 500 ng CRF and 20 µg amphetamine increased the ability of the 
sucrose CS+ cue (but not CS-) to trigger enhanced responding on the previously sucrose-associated lever (but not on the con-
trol lever). B. Transform scores show a direct contrast between CS+ and CS- effects of lever pressing. CS+ effects on cue-trig-
gered lever pressing are amplified by CRF (500 ng) and by amphetamine (20 µg) microinjections.
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CS+ versus CS- by subtracting CS- pressing from CS+
pressing on a within-subject basis, so that the remainder
shows the enhanced CS+ effect for each individual rat.
When we calculated this, the resulting transfer scores con-
firmed that both the CRF high dose (500 ng) and amphet-
amine (20 µg) microinjections significantly and
specifically amplified the incentive effect of the CS+ on
pressing the sucrose-associated lever, compared to vehicle
and low dose CRF microinjections (Figure 3).
Thus, CRF (500 ng) and amphetamine (20 µg) magnifica-
tion of cue-triggered peaks in lever pressing applied only
to the CS+ that previously was associated with sucrose
Temporal pattern of lever pressing within test session Figure 4
Temporal pattern of lever pressing within test session. Minute-by-minute time-course of lever pressing peaks on 
sucrose-associated lever after microinjections of (A) vehicle, (B) amphetamine 20 µg, (C) CRF 500 ng, and (D) CRF 250 ng. 
Open circles depict lever pressing during presentation of the 30-sec CS- and filled circles during presentation of the CS+. Lever 
pressing is also shown during the 30 sec period before each CS+ or CS- (precue baseline), and during the 30 sec period that 
followed each CS+ or CS- (post-cue period). Both CRF (500 ng) and amphetamine (20 µg) magnified intense, transient, revers-
ible, and repeatable peaks in pressing on sucrose-associated lever each time the CS+ occurred. Magnified lever pressing after 
CRF (500 ng) or amphetamine (20 µg) was triggered by each presentation of the sucrose cue, but then was followed by a rapid 
descent back to normal baseline levels of pressing once the cue ended (B and C).
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UCS, and not to the control CS- which did not signal
sucrose.
Temporal reversibility of cue-triggered pursuit: 
dependence on CS+ presence
If increased lever pressing for reward is caused by excessive
attribution of incentive salience to the reward's CS+, then
the temporal pattern of peaks of cue-triggered responding
should be phasic, reversible, and repeatable [30,31]. In
other words, peak bursts of active lever pressing should
come and go with successive presentations of the 30-sec
CS+, and disappear again soon after each presentation. A
temporal analysis of responding confirmed this pattern
for CRF (500 ng) and amphetamine (20 µg) enhancement
of pressing on the sucrose-associated lever during CS+
presentations (Figure 4). A magnified peak of pressing on
the lever previously associated with sucrose reward was
triggered anew by each presentation of the CS+ sucrose
cue after CRF (500) or amphetamine microinjections,
maximally elevating during its 30-sec period (Two-way
ANOVA (cue presence × cue presentation order), F1,79 =
16.11, p < 0.001; main effect of cue presence). Pressing
rose within seconds of each CS+ and remained dramati-
cally elevated throughout the 30 sec presentation. After
almost every CS+, pressing decayed significantly within 1
min of its end, and always descended to baseline levels
again before the next CS occurred 4 min later.
This temporal pattern of cue-triggered phasic peaks of
pressing (without enhancing intervening plateaus or CS-
pressing) is important because it further rules out alterna-
tive explanations mentioned above, based on traditional
CRF/amphetamine effects that have more constant time
course durations (i.e., on the order of several minutes or
more). Those include increased motor arousal, general
impulsiveness or aversive states that would last longer
than 30 sec, and so should be present during no-stimulus
baseline periods (and CS- presentations) between CS+
tones. By contrast, the enhanced incentive salience inter-
pretation specifies that CRF should specifically amplify
attribution only to the reward CS+, just as amphetamine
microinjection does, and so seems to fit best this observed
pattern of effects.
Target specificity of cue-triggered incentive motivation: 
active versus inactive levers
Cue-triggered increases in efforts to obtain sucrose were
directed specifically to the active lever that had previously
earned sucrose reward during training, and not to the
other lever (Two-way ANOVA (drug × lever), F3,79 = 3.25;
p < 0.05, significant interaction; Figure 4). Rats made few
responses on the second control lever that had never been
associated with sucrose reward. Pressing on the control
lever was not increased during the CS+ by either CRF (500
ng) (Two-way ANOVA (drug × cue presence), F2,59 = 0.35,
p = 0.55, n.s.) or amphetamine (20 µg) (Two-way ANOVA
(drug × cue presence), F2,59 = 0.36, p = 0.55, n.s.). Lever
specificity was further confirmed by finding a significant
difference between previously-active lever versus always-
inactive lever in pressing during CS+ (Two-way ANOVA,
F1,159  = 5.12, p < 0.05), and a significant interaction
between lever identity and drug in the microinjection-
induced enhancement of cue triggered increases in press-
ing (Two-way ANOVA (drug × lever), F1,159 = 34.15; p <
0.001). Thus, the CS+ sucrose cue selectively triggered
increased pressing only on the lever previously associated
with obtaining sucrose. That suggests that our CRF incen-
tive on PIT lever pressing are not explained by nonspecific
motor arousal induced by CRF, or a general sensorimotor
tendency to emit more pressing movements regardless of
target, even if CRF produced any motor or arousal effects
(Figure 4).
Pavlovian approach CRs to sucrose dish
Presentations of CS+ also elicited Pavlovian approach
conditioned responses to the sucrose dish (especially after
vehicle microinjections), either as a Pavlovian S-R habit
elicited by the CS+, or as a discriminative instrumental
response to earn sucrose. However, CRF and ampheta-
mine microinjections both suppressed conditioned dish
approach below the vehicle control level (F3,159 = 2.79, p
< 0.05; Figure 5). That suppression is noteworthy because
it helps rule out the several remaining alternative explana-
tions. For example, approach suppression by CRF indi-
cates that the enhancement of PIT cannot be due to CRF
potentiation of S-R Pavlovian habits, because dish
approach was the only S-R habit ever actually paired with
CS+ tone during training. Similarly, approach suppres-
sion indicates that CRF did not potentiate discriminative
instrumental responding (in which the CS+ might have
acted as a discriminative stimulus (SD) to signal that
instrumental approach would be reinforced, and this
instrumental relation might later have been generalized to
lever pressing [41,42] because any such instrumental rela-
tion between approach and reinforcement was actually
suppressed by CRF and amphetamine during the PIT test,
and not enhanced. Sucrose dish entries during the first
CS+ were especially suppressed by both CRF doses (Two-
way ANOVA (drug × cue presence), F2,79 = 4.21, p < 0.01).
Sucrose dish approaches were similarly suppressed by
amphetamine microinjection (F1,39 = 6.40, p < 0.05). Sup-
pression of dish approach during the CS+ by CRF and
amphetamine may have occurred possibly as a secondary
consequence of increased response competition from
higher cue-triggered rates of lever pressing that occurred at
the same time.
The suppressive effects on dish approach CRs after micro-
injection of CRF or amphetamine were associatively spe-
cific to the CS+ (drug × CS+ interaction, F1,39 = 6.40, p <BMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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0.05) (Fig. 3), and the same was true for amphetamine
microinjection (drug × CS+ interaction, F1,39 = 5.34, p <
0.05). Neither CRF nor amphetamine microinjections
decreased food cup entries below vehicle levels during the
baseline 30 s pre-cue periods (2-way ANOVA, significant
interaction (drug × cue presence), F3,79 = 3.47, p < 0.05) or
during CS- presentations (drug × CS+ interaction, F1,39 =
3,25, p = 0.68, n.s.).
Finally, we note that CRF effects on PIT versus dish
approach were independent and partially dissociable by
dose: both 250 ng and 500 ng CRF doses suppressed cue-
triggered dish approach during CS+ presentations early in
a session, but only 500 ng CRF increased lever pressing.
That indicates that suppression of dish approach is not a
sufficient cause of CRF enhancement for cue-triggered
lever pressing, which appears to require independent
incentive motivation mechanisms recruited by the higher
dose.
Fos plumes: identifying zones of local neuronal activation
To help identify where our CRF microinjections actually
acted in the brain we used a Fos plume mapping proce-
dure to visualize spread of neuronal gene transcription
triggered by 500 ng CRF in tissue around microinjection
sites [43-45]. The local expression of Fos protein is a use-
ful marker for geographic spread of pharmacological
impact, even if c-fos transcription is not invariably tied to
neuronal activation, at least for drugs that induce acute
Fos transcription immediately around a microinjection
site (including CRF). Measuring the size of the resulting
local Fos plume caused by a microinjection objectively
assesses the spherical volume of tissue and intensity of
neuronal response impacted by local drug action. Fos
expression in a local neuron might either reflect direct
drug action on receptors on that neuron, or else reflect
indirect action from adjacent neurons containing recep-
tors that act on Fos-expression neurons via local circuits.
In either case, the Fos plume reflects a local sphere of func-
tional modulation induced by CRF microinjection, and
provides quantitative information on its intensity and
size. The boundaries of the plume reveal where the drug
stops having an intense functional impact, even if drug
molecules spread further beyond the plume in lower con-
centrations insufficient to trigger gene transcription.
For microinjections of CRF (500 ng) we identified two
zones of elevated Fos expression: intense versus moderate
Response competition between sucrose dish approach and lever pressing Figure 5
Response competition between sucrose dish approach and lever pressing. A. Averaged time-course of approach 
responses to sucrose dish just before, during and after first CS+ cue presentation. B. Same information for pressing on 
sucrose-associated lever. Each panel compares cue-triggered responding after microinjections of vehicle (white circles), CRF 
500 µg (green circles), CRF 250 µg (blue circles), or amphetamine 20 µg (red circles). Both CRF and amphetamine reduced the 
peak of cue-triggered approaches to the sucrose dish, but simultaneously increased cue-triggered lever pressing. It is impossi-
ble to perform both actions at exactly the same time, and so conditioned dish approaches may have been suppressed as a 
result of response competition from increased lever pressing that occurred during the same 30-sec period.
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elevation zones (Figure 1). Each zone was defined by 2
independent criteria. An inner zone of intense Fos eleva-
tion was defined as the mean radius within which 1) abso-
lute Fos expression was increased by at least 1 order of
magnitude over normal tissue levels (10 times spontane-
ous levels in medial shell), and 2) relative Fos expression
was increased by at least twice over the levels produced at
equivalent locations after vehicle microinjections (2 times
vehicle-induced levels). An outer zone of moderate Fos
elevation was defined at the mean radius within which 1)
absolute Fos expression was increased by 3 times (but not
10 times) over normal tissue levels, and 2) relative Fos
expression was increased by 5 times over the level of
equivalent points after vehicle locations (note: the reason
why our outer zone used a higher vehicle-relative thresh-
old than the inner zone was that a vehicle microinjection
induces some Fos expression in a small centrally-restricted
inner zone, perhaps due to pressure of the microinjection
or irritation from cannula-induced damage. The resulting
slight elevation in inner zone vehicle baseline [above nor-
mal tissue baseline] imposed a ceiling on drug-induced
Fos expression in this central zone that limited relative
increases to under 5× [even if drug caused a >10× absolute
increase]).
The mean inner zone of intense Fos elevation produced by
CRF microinjection at the behaviorally most effective
dose (500 ng) was approximately 0.25 mm in radius
(absolute 10× increase over normal; relative 2× increase
over vehicle) and the outer zone of low elevation was an
additional 0.2 mm radius (absolute 5× increase over nor-
mal; relative 5× increase over vehicle; Figure 1). Therefore,
to represent these zones we assigned color-coded symbols
of corresponding 0.25 mm radius in size to represent each
inner zone, surrounded by similarly colored but more
pale halos of additional 0.2 mm radius to represent each
outer zone. Thus symbols and halos served to bracket the
estimated range of intense-moderate functional activation
likely to mediate the mapped microinjection effects on
behavior.
To calculate the 3-dimensional plume volume produced
by CRF 500 ng microinjections, we assumed a roughly
spherical shape and calculated the inner intense sphere to
contain a volume of approximately 0.06 mm3, and the
outer sphere to contain a volume of approximately 0.38
mm3. Because the entire medial shell is approximately
2.87 mm3 in total volume, these volumes meant that the
inner sphere of a CRF (500 ng) plume filled approxi-
mately 2% of total medial shell volume, whereas its outer
sphere filled approximately 13%. Of course, some micro-
injections near borders may not have filled the shell to
quite that extent if they partially penetrated other struc-
tures such as the medial core (though adjacent penetra-
tion was never deeper than 0.5 mm).
We mapped the extent of activation diffusion as reflected
by Fos plume around each microinjection site. In order to
further assess the role of diffusion into other structures or
the ventricles, we took two additional steps. First, we com-
pared PIT effects for 'hits' in nucleus accumbens shell ver-
sus 'missed' anatomical control sites in lateral septum
dorsal to the nucleus accumbens. No enhancement of PIT
by CRF or amphetamine was evident in rats with dorsal
anatomical control sites outside the nucleus accumbens
(Figure 5), indicating that the PIT enhancement effects
described above was not due to diffusion upwards along
cannulae tracks to dorsal structures. Second, we inspected
individual brain slices to identify any sites in medial shell
where the Fos plume could touch the wall of the lateral
ventricle. This seemed worth doing because intra-ven-
tricular CRF administration in the 1000 ng range has been
reported to produce arousal and conditioned aversion
effects, and so conceivably might have been responsible
also for PIT magnification effects here. To assess if leakage
into ventricles was the primary source of CRF effects here,
we compared magnitude of PIT enhancement by CRF in
rats with Fos plumes that touched the ventricle wall versus
the group of rats with plumes contained entirely within
the nucleus accumbens. Two rats had plumes that defi-
nitely touched lateral ventricle, and another two had
plumes that might have touched, whereas 6 rats had
plumes fully contained away from the ventricle wall. By
themselves, the group of 4 rats with ventricle-touching
plumes did not show a significant PIT enhancement effect
by CRF (mean score 2.7, SEM = 1.3; F1,7 = 2.03, p = 0.20).
By contrast, the group with non-touching plumes con-
tained fully within nucleus accumbens away did show an
enhancement of PIT by CRF microinjection (mean score
3.33; SEM = 1.17; F1,63 = 10,17, p < 0.05). That pattern
across groups indicates that the significant PIT enhance-
ment effects described above were not driven primarily by
CRF ventricle diffusion in this group. Finally, we found no
significant difference between these two groups (F1,9 =
0.10, p = 0.75), indicating that most sites tested in nucleus
accumbens contributed comparably to the PIT effects
described above.
Functional Fos plume mapping of microinjection effects on 
behavior
Functional site effects were mapped for all cannulae place-
ments in nucleus accumbens and adjacent structures (Fig-
ure 2). Colors for symbols and halos represented the
magnitude of behavioral effects produced by CRF (500
ng) microinjections at each microinjection site change
score in elevation of pressing on sucrose-associated lever
minus to the control vehicle effect at that same site in the
same rat). We chose the sagittal plane primarily to map
Fos plumes and functions because sagittal view allows the
entire rostrocaudal and dorsoventral extents of medial
shell to be viewed on a single atlas map (Figure 2). Addi-BMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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tional supplemental maps were also constructed in coro-
nal and horizontal planes to allow full 3-D mapping of
functional effects [46].
The Fos plume maps for localization of function showed
that most nucleus accumbens microinjections were suc-
cessfully placed in the intended posterior-central zone of
medial shell that has highest levels of CRF receptors and
terminals, and within that target zone most CRF (500 ng)
microinjections produced comparable magnifications of
PIT (Figure 2). The spread of local Fos plumes did not oth-
erwise extend to other structures around the medial shell,
including dorsal structures, except that a few microinjec-
tions may have penetrated approximately 0.4 mm into the
medial border of nucleus accumbens core.
Although more remains to be done in future regarding
localization of CRF function for incentive motivation in
nucleus accumbens and related structures, these initial
maps indicate that CRF activation in our present study
was restricted to the nucleus accumbens medial shell, and
possibly a small strip of adjacent core. Within that zone of
medial shell, CRF activation appears sufficient to magnify
the level of incentive salience attributed to a CS+ that was
previously associated with reward (Figure 2).
Discussion
Our findings show that a CRF subsystem in nucleus
accumbens can magnify the positive incentive motivation
triggered by a cue previously associated with reward
(CS+), and so spur appetitive behavioral pursuit of that
reward. CRF (500 ng) microinjections in medial shell of
nucleus accumbens directly increased cue-triggered instru-
mental lever pressing behavior aimed at that sucrose
reward, without increasing behavior in the absence of the
Pavlovian CS+ or reward cue. The CRF-induced pattern of
excessive cue-triggered pursuit of reward appeared
remarkably similar to that caused by amphetamine micro-
injection in the same rats at the same sites [30,31], sug-
gesting that both CRF and amphetamine in the nucleus
accumbens may prime cue-triggered seeking of incentives
via overlapping mesolimbic mechanisms. This is the first
specific evidence to support the hypothesis that a brain
limbic CRF sub-system can magnify any purely positive or
appetitive motivational process, such as increased incen-
tive salience, to spur cue-triggered pursuit of rewards [10].
Perceptual synergy of cue with CRF/amphetamine 
incentive salience attribution
Enhancement of instrumental lever pressing co-depended
on the simultaneous presence of CRF (or amphetamine)
microinjection in nucleus accumbens plus the Pavlovian
auditory cue in the environment that previously was asso-
ciated with sucrose reward (Pavlovian CS+). Neither CRF
nor cue alone was sufficient to produce maximum peaks
of incentive motivation. Each time the CS+ was presented
to a rat after CRF microinjection its lever pressing was dra-
matically magnified to a peak roughly double the level
shown by the same rat before and after that CS+ (i.e., com-
pared to either during absence of any CS [baseline] or dur-
ing the CS- that did not predict sucrose reward), and
roughly 300% over normal peaks that rat showed during
the same CS+ on tests after control vehicle microinjec-
tions. Each cue-triggered peak lasted approximately 1
min, and instrumental responding then always fell back
to control levels (Figure 3).
This selective pattern of enhancement limited to CS+ indi-
cates that motivation enhancement was not a tonic conse-
quence of CRF effects that lasted minutes or more (e.g.,
due to motor arousal or aversive state effects). Instead cue-
triggered incentive motivation came and went with each
CS+ as an intense time-locked phasic, reversible and
repeatable peak, fitting the prediction of the hypothesis
that CRF in nucleus accumbens can magnify the incentive
salience of cues associated with reward, rather than
directly driving increased levels of appetitive behavior in
the absence of reward cues. This reversible CRF pattern is
highly similar to the cue-locked enhancement pattern of
amphetamine observed here and in previous experiments,
a pattern that originally helped implicate identify incen-
tive salience features mediated by mesolimbic dopamine
systems [30,31].
Ruling out alternative explanations
Not hedonic self-medication or reinforcement?
The ability of stress to promote pursuit of rewards is in a
sense over-explained by traditional interpretations. That
is, there are many different potential alternative explana-
tions already available that may apply to some cases of
real-world stress (e.g., stress self-medication, aversion
escape, frustration or general arousal), and even more
alternatives introduced in various animal models of trig-
gered-relapse (e.g., discriminative instrumental SD signal-
ing of reward availability). The potential over-abundance
of explanations makes it especially important to rule out
traditional ones before positing any new explanation,
such as the hypothesis that CRF in nucleus accumbens
magnifies an appetitive or positive motivation mecha-
nisms such as cue-triggered incentive salience. So it is
worth briefly summarizing how features of CRF results in
the pure incentive PIT procedure used here eliminate tra-
ditional alternatives that might otherwise have explained
CRF's amplification of cue-triggered incentive motivation
for reward.
A common view of how stress might motivate binge eat-
ing and food intake, addictive drug relapse, gambling, or
other excessive reward pursuit is to induce anhedonia,
dysphoria, frustration, or related negative aversive statesBMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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that individuals try to counteract by pursuing and con-
suming hedonic rewards [21,47]. CRF may indeed pro-
duce aversive states at many brain sites. However, several
observations rule out aversion escape or mood enhance-
ment by reward consumption as explanations for CRF's
enhancement of cue-triggered incentive motivation for
sucrose. First, rats never obtained any primary sucrose
reinforcement while under CRF effects, and so no sucrose
consumption ever actually improved their hedonic state
during test. Further, amphetamine microinjection, which
is generally thought to produce positive motivational
effects via mesolimbic dopamine and related neurotrans-
mitter activation, produced exactly the same pattern of
enhanced cue-triggered incentive motivation as CRF. Most
important, if CRF caused a negative state that maintained
increased seeking of sucrose, then that pharmacological
state should have remained visible throughout most of
the half-hour test. Again, however, tonic elevation was not
expressed in lever pressing; instead elevated peaks of lever
pressing came and went with the auditory CS+ stimulus
under CRF. Finally, it is relevant to note that the CS+
could not have acted as an instrumental discriminative
stimulus to signal sudden sucrose availability, because our
rats had never in their lives been instrumentally rein-
forced for pressing the lever in the presence of the CS+
(not even during training), and instead the only behavio-
ral response that had ever earned sucrose before was actu-
ally reduced during CS+ by CRF (dish approach). Overall,
therefore, it is not plausible that CRF caused rats to press
more as an instrumental attempt to escape or reduce a per-
sistent negative hedonic state.
Not sensorimotor arousal?
Several of the same considerations also rule out other
alternative explanations for our results such as CRF-
induced arousal, psychostimulant or accelerant, or gen-
eral sensorimotor activity effects. For example, although
CRF in the nucleus accumbens does indeed cause
increased locomotion and grooming behavior [48], that
chronic state-like consequence would apply over most of
the entire 30-min test regardless of whether CS+ was
present or absent. But baseline pressing was not elevated
in the absence of CS+, and that cue-triggered pattern of the
sucrose-lever increase, together with the lack of increase
on the inactive lever, seem to rule out elevated general
motor arousal as explanation for CRF's ability to magnify
cue-triggered peaks of incentive motivation
Interaction with other CRF and limbic systems
We emphasize that our finding that CRF in medial shell of
nucleus accumbens causes increased incentive salience
attribution to reward CS+ does not contradict traditional
notions that CRF systems in other brain structures may
mediate mostly negative or aversive stress effects. Nor
does it contradict suggestions that some appetitive behav-
ior seen in stress may reflect attempts to reduce those aver-
sive effects. However, it shows that the alternative
phenomenon of enhanced positive incentive motivation
triggered by reward-related cues may co-occur when gen-
erated by some CRF subsystems, such as in the medial
shell of nucleus accumbens. This conclusion implies that
blocking aversive effects per se may not be enough to
block the increased in appetitive pursuits produced by
stress. Instead, the increase in cue-triggered pursuit of
incentives follows rules that govern the attribution of
incentive salience to Pavlovian conditioned stimuli for
reward [37,49].
The similar enhancements by CRF and amphetamine of
cue triggered incentive motivation indicates it might be of
future interest to examine potential interactions between
CRF and mesolimbic dopamine or corticolimbic gluta-
mate projections in modulating reward cue signals in
nucleus accumbens. Interaction is compatible with
reports that, for instance, aversive stressors can cause
dopamine release in nucleus accumbens (which has
sometimes been used to argue against a purely positive
motivational role of dopamine) [50,51]. Regardless of the
role of dopamine per se in stress, CRF might interact with
mesolimbic mechanisms of incentive salience in nucleus
accumbens either directly or by modulating dopamine-
related and/or glutamate-related signals [52]. We caution
that, although potential interaction might possibly seem
to imply that CRF antagonists could be used therapeuti-
cally to reduce excessive incentive salience in stress, the
actual effect of CRF receptor manipulation on dopamine
release in nucleus accumbens may involve complexities
that could complicate such predictions. For example, the
CRF-1 antagonist CP-154,526 has been reported to
increase cocaine-associated dopamine release, at least in
rostral shell of nucleus accumbens and pre-frontal cortex
[53], and so any speculation about the potential relation
of CRF antagonists to incentive salience must await future
empirical investigation.
Conclusion
Paradoxical positive incentive motivation magnification 
by CRF systems in nucleus accumbens?
Everyone agrees that stress is predominantly an aversive
motivational state. Similarly, CRF delivered to hypothala-
mus and amygdala may produce predominantly aversive
effects, which typically suppress appetitive behaviors such
as normal food intake [54]. However, our findings indi-
cate that particular CRF subsystems, particularly in
nucleus accumbens, magnify a positive motivational
process triggered by reward cues that independently spurs
pursuit of reward. Specifically, our results that CRF recep-
tor activation in medial shell of nucleus accumbens
directly increase the attribution of incentive salience to a
CS+ that was previously associated with reward. PhasicBMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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cue-triggered peaks of incentive motivation to obtain
sucrose reward are seen whenever a synergistic combina-
tion of conditions is met: simultaneous CS+ or cue pres-
ence plus CRF co-activation in nucleus accumbens. CRF's
magnification of cue-triggered incentive salience appears
remarkably similar to effects of amphetamine in nucleus
accumbens, suggesting that stress and addictive drugs
might both prime excessive cue-triggered seeking of incen-
tives via overlapping mesocorticolimbic mechanisms.
One possibility for a natural role is that CRF nucleus
accumbens systems might ordinarily be activated in con-
junction with stress-related glucocorticoid elevation. That
seems consistent with demonstrations that HPA activa-
tion and glucocorticoid hormones may contribute to
binge eating, drug addiction, and other excessive reward
pursuits [22,55]. Glucocorticoids actually increase CRF
expression in structures such as amygdala and BNST, and
conceivably in accumbens shell too [56,57]. Thus, stress
and glucocorticoids might 'energize' goal directed behav-
iors in part by activating CRF accumbens mechanisms that
amplify the incentive salience of stimuli associated with
reward [56,58]. Future studies will be needed to address
the question of how CRF interacts with glucocorticoids,
dopamine, and other limbic neurochemical systems to
modulate incentive salience.
Our results suggest that although stress and hypothalamic
CRF have predominantly aversive motivational effects,
activation of CRF systems in the medial accumbens shell
can actually enhance appetitive behavior via purely posi-
tive motivational effects. This provides a novel explana-
tion for why stress may sometimes exacerbate cue-
triggered binge eating, drug addiction relapse, and other
excessive pursuits of rewards.
Methods
Subjects
Experimentally naïve male Sprague Dawley rats (n = 23),
(born at the University of Michigan; 230–260 gm at the
beginning of the experiment) were housed in pairs in
plastic tub cages under a reverse 12 hr light cycle (lights off
at 7:00 a.m.). Rats were divided into two groups that
received identical surgery for implantation of microinjec-
tion cannulae; one group (n = 14) was used for behavioral
training and testing, cresyl violet histology and ink cannu-
lae localization, and the other group (n = 9) was used for
Fos plume analyses under microinjection conditions
identical to the first behavioral test day. Rats were given
15–20 gm of rat chow each day during the experiment and
tap water was provided ad libitum in the home cage. All
studies were approved by the University Committee on
Use and Care of Animals of the University of Michigan in
compliance with National Institutes of Health standards.
Test chambers
Training and testing took place in computerized operant
chambers (Med Associates Inc., St. Albans, VT). Each
chamber contained a sucrose cup (with photobeam entry
detector), two levers, and speaker modules (clicker and
tone). A 3 W, 24 V house light mounted on the top-center
of the wall opposite the magazine provided illumination.
Sound attenuating boxes equipped with ventilation fans
masked external noise. A computer equipped with MED-
PC software (Med Associates) recorded the number of
active and inactive lever presses and food cup entries. A
videocamera positioned below the transparent floor
recorded the rat's behavior for subsequent slow-motion
analysis.
Behavioral measure of incentive salience motivation
Phasic peaks in incentive salience attributed to reward
that were triggered by sudden presentations of an associ-
ated CS+ (cue-triggered incentive motivation) were meas-
ured in a pure conditioned incentive paradigm based on
Pavlovian-Instrumental transfer (PIT). It is important to
note that PIT procedures by themselves are not pure meas-
ures of incentive salience, as PIT effects contain both moti-
vational and specific UCS-signaling information
components. Instead the procedures must be carefully
designed to conform to pure incentive rules and exclude
alternative interpretations (e.g., test in extinction, preserve
instrumental baseline unchanged, etc). Our pure incen-
tive PIT has been designed to do just that.
Instrumental training (days 1–17)
We used a variable interval schedule (with ascending lev-
els of responding demand) for instrumental training to
produce low but stable instrumental responding in the
face of extinction that would optimally reveal the motiva-
tional form of Pavlovian instrumental transfer relevant to
incentive salience. Rats were initially given overnight
sucrose pellets twice in their home cages to familiarize
them with the reward and overcome neophobia (days 1
and 2). All animals received next two sessions of maga-
zine training (days 3 and 4) in which 20 deliveries of a sin-
gle 45 mg sucrose pellet (Formula F; P.J. Noyes Co.,
Lancaster, PA) were freely given on a fixed time (FT), 1
min schedule of reinforcement. Then animals were shifted
to a variable interval (VI)-1 instrumental reinforcement
schedule (each reward was delivered on average every 5
seconds after at least one lever press) (days 5–7). Presses
on one lever in the operant chamber produced sucrose
pellets, whereas presses on the other lever did not, and
served only as control for sensorimotor effects. Active and
inactive lever assignments were balanced across rats. The
schedule of reinforcement for the active lever was progres-
sively increased to VI-5 (days 8–11), VI-10 (days 12–14)
and VI-30 (days 15–17).BMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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Pavlovian training (days 18–31)
Pavlovian conditioning took place immediately after
instrumental training. Both levers were absent from the
chambers during Pavlovian conditioning to prevent
adventitious reinforcement of a lever pressing habit dur-
ing the cue, and to eliminate possibilities of pairing the
CS+ with a lever pressing habit. Auditory stimuli each last-
ing 30 sec were arbitrarily designated as CS+ and CS-: an
auditory clicker stimulus (60 dbs) and a pulsed tone stim-
ulus (2.9 kHz, 60 dbs, continuous pulsing 0.5 sec on/off).
During 14 daily sessions, rats received 10 pairings of the
CS+ (30 sec duration) followed by immediate delivery of
three sucrose pellets [unconditioned stimulus (UCS)].
Similar to previous PIT studies, we wished the CS- to serve
as a control stimulus that was essentially irrelevant to
reward and rewarded performance, rather than to sup-
press instrumental pressing as would either a novel stim-
ulus or a strongly negative stimulus that was extensively
paired with reward omission [59]. Therefore the CS- (30
sec duration) was presented twice during the last three
Pavlovian sessions (at the middle and end of each ses-
sion) and was never followed by sucrose pellets [29]. Nose
entries into the sucrose dish were monitored by photo-
beam detector, and all rats developed a discriminative
approach conditioned response (CR) to the sucrose dish
during the CS+ but not during the CS- (CR difference
scores were calculated to verify acquisition as approaches
during 30 sec CS minus approaches during 30 sec baseline
immediately before that CS).
Microinjection cannula surgery
Rats were pretreated with 0.1 ml of atropine sulfate, anes-
thetized with a mixture of ketamine HCL (80 mg/kg, i.p.)
and xylazine (5 mg/kg) and stereotaxically implanted
with bilateral 23 gauge guide cannulae targeted at the
medial shell of the nucleus accumbens. A slanted skull
position was used, with the incisor bar set at +5 mm above
interaural zero to achieve a slanted cannula angle and
avoid penetrating the lateral ventricles. Cannulae were
aimed at the caudal half of the accumbens: 2.8-2.2 mm
anterior to bregma, 0.9 mm lateral to the midline, and 5.7
mm ventral to the skull surface (2.0 mm above the injec-
tion site), based on the atlas of Paxinos and Watson
(1996). These coordinates corresponded to the following
coordinates with a flat skull: 1.2-0.7 mm from bregma,
0.9 mm from midline and 7.0 mm from the skull. The
cannulae were anchored with skull screws and cranial
cement, and wire stylets were used to prevent cannula
occlusion. Animals were allowed to recover for seven days
before testing.
Final lever retraining and extinction pre-exposure (days 32 
and 33)
Before testing, rats were given two additional instrumen-
tal training sessions to re-establish instrumental lever
pressing (VI-30 sec schedule), followed by two instrumen-
tal extinction days (days 34 and 35) with levers present
but no sucrose to habituate animals to the extinction con-
dition.
Drugs and microinjections
Bilateral microinjections of vehicle (sterile isotonic
saline) or corticotropin releasing factor (human CRF, 250
and 500 ng/0.2 µl per side; Sigma St. Louis, MO) were
selected based on previous CRF microinjection studies.
For example, 500 ng in the nucleus accumbens increased
activation general behavioral activity counts, whereas 125
or 250 ng did not (and neither dose did when adminis-
tered in lateral ventricles, consistent with an accumbens
site of action) [32].
D-amphetamine sulfate (20 µg/0.2 µl per side; Sigma St.
Louis, MO) has been previously found to increase cue-
triggered incentive motivation in this pure conditioned
incentive (PIT) paradigm after microinjections into
nucleus accumbens shell [24 and 25] and was used as a
'gold standard' for increased CS+ incentive salience to
compare against CRF effects within each rat. CRF 250 and
500 ng doses were chosen because they have previously
been found to produce grooming, sniffing and oral motor
behavioral effects when microinjected in nucleus
accumbens shell [48]. Microinjections were made with a
stainless steel injector cannula (29 gauge), extending 2.0
mm beyond the ventral tip of the guide, and attached to a
syringe pump via PE-20 tubing. Rats were gently hand-
held during the bilateral microinjections (0.2 µl at a rate
of 0.30 µl/min via syringe pump). After infusion, the
injectors remained in place for an additional 60 sec to
allow for drug diffusion before the obturators were
replaced.
Conditioned incentive testing of cue-triggered incentive 
motivation (days 36–42)
On each of 4 test days rats were given bilateral microinjec-
tions of either vehicle (0.2 µl), CRF (250 or 500 ng/0.2 µl)
or amphetamine (20 µg/0.2 µl) and placed back in their
cages. The order of microinjection was counterbalanced
across rats, and test days were spaced 48 hrs apart. After 15
min (approximately when behavioral effects such as CRF-
induced grooming or amphetamine-induced locomotion
began to be observed), rats were placed in the instrumen-
tal chambers with both levers present (days 36, 38, 40 and
42) for a 32.5 min test session for Pavlovian-Instrumental
transfer). Instrumental performance was assessed under
extinction conditions, so no sucrose pellets were given at
any time during the test. In each test session, the CS+ and
CS- were each presented four times for 30 sec each presen-
tation (first CS+ or CS- presented at 2.5 min; fixed time 4
min interval; alternating CS+/CS- order). Presses on both
previously-active and previously-inactive levers wereBMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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recorded automatically during each 30 sec CS+ and CS-
presentation, during the 30 sec period immediately pre-
ceding each CS+/CS- (baseline), and during the 30 sec
period immediately after each cue presentation. Sucrose
dish entries were also recorded during these periods.
Statistical analysis
Each rat served as its own control for within-subjects
ANOVA comparison of drug and CS effects on instrumen-
tal lever pressing responses and on dish approach Pavlo-
vian CRs (vehicle vs drugs across test days; CS+ vs baseline
vs CS- within test session). Lever pressing totals during
each period were square root transformed (SQRT) to
achieve homogeneity of variance as assessed by the
Mauchly Sphericity test prior to ANOVA. Differences
scores for cue-triggered effects of each CS were obtained
by subtracting the number of responses during each base-
line precue period from responses during its subsequent
CS+ or CS- presentation [29]. Within subject three-way
ANOVAs were performed to examine the effects of lever
(active vs nonactive), cue drug microinjection (vehicle,
CRF 250 and 500 ng) and discriminative cue type (CS+ vs.
CS-). The effects of drug administration on baseline lever
pressing (30 s precue time period) was also assessed, as
was the order of cue presentation within a cue session
(first, second, third or fourth), using 2-way ANOVAs.
Whenever main effects or interactions were found, the
Bonferroni method was used for post hoc comparisons.
Similar analyses were performed for entries into the
sucrose dish.
Histology
Following the completion of testing, rats were deeply
anesthetized with sodium pentobarbital, microinjected
either with CRF (500 ng) or ink and 1-hr later perfused
transcardially with buffered saline, followed by a buffered
4% paraformaldehyde solution. The brains were
removed, post-fixed, sectioned (40 µm), and mounted on
slides. Brain slices were prepared for one of 2 analyses: 1)
densities and diameters were measured for local Fos
plumes caused by microinjections of CRF or vehicle in a
group of rats not used for behavioral tests; 2) microinjec-
tion centers were mapped by ink microinjection and cre-
syl violet staining in all rats used for behavioral testing.
Two animals were found to have placements located out-
side of the nucleus accumbens shell and so were consid-
ered separately to yield a final total of 10 subjects with
accurate placements in medial shell.
Fos-like protein immunohistochemistry
Fos plumes were measured in rats that were microinjected
bilaterally in medial shell of nucleus accumbens with the
most behaviorally effective doses of 500 ng or vehicle.
Seventy-five minutes after microinjection, rats were
deeply anesthetized with sodium pentobarbital prior to
transcardial perfusion. Brains were removed and placed in
4% formaldehyde for 2 hours, placed in 30% sucrose
overnight, and then sectioned at 50 µm and stored in 0.2
M NaPb (pH 7.4). To visualize Fos-like immunoreactivity,
we used the avidin-biotin procedure [60]. Brain sections
were immersed in blocking solution (3% normal goal
serum (NGS) and 0.3% Triton X-100 in TPBS) for 1 h and
then incubated at room temperature for 24 h with a rabbit
polyclonal antiserum directed against the N-terminal
region of the Fos gene (Sigma, St Louis; dilution of 1:5000
in TPBS, 1% NGS and 0.3% Triton X-100). To reduce
background staining the antiserum was preabsorbed with
acetone-dried rat liver powder overnight at 4°C. After the
primary antibody incubation, tissue was exposed to goat
anti-rabbit, biotinylated secondary IgG (Santa Cruz Bio-
chemicals, California; diluted 1:200) and then to avidin-
biotin-peroxidase complex for 1 h at room temperature. A
nickel diaminobenzidine (Nickel-DAB) glucose oxidase
reaction was used to visualize Fos-like immunoreactive
cells. Finally, sections were washed in Tris buffer,
mounted from ddH2O, air-dried, dehydrated in alcohol,
cleared in xylene and coverslipped. Fos-like immunoreac-
tivity was visualized using a Leica microscope coupled to
a SPOT RT slider (Diagnostic Instruments, MI) using
SPOT software (SPOT version 3.3).
Fos plume identification
Our procedure for measuring Fos plumes immediately
surrounding a local microinjection site that are induced
by drug was modified slightly from one previously
described [43-45]. Briefly, Fos-labeled cells on tissue sur-
face with 5x–40x magnification were counted individu-
ally within blocks (125 µm × 125 µm) at point locations
spaced at 125 µm intervals along each of 7 radial arms
emanating from the center of the microinjection site (45°,
90°, 135°, 180°, 225°, 270°, 315°; Figure 1).
Fos densities were measured 1) in normal nucleus
accumbens medial shell tissue of brains without a micro-
injection cannula to assess normal baseline expression, 2)
around the site of vehicle microinjections to assess can-
nula track and vehicle-induced Fos baseline expression,
and 3) around the site of CRF microinjections to assess
drug-induced elevations of local Fos expression (Figure
1).
Fos plumes surrounding drug microinjections were
mapped as zones of intense or moderate elevation of Fos
expression, identified in two ways: 1) as absolute
increases over medial shell normal levels (elevation by 10
times [intense] or 5 times [moderate] normal tissue
counts sampled in the absence of any cannula track, and
2) as vehicle-relative increases caused by drug (elevation
by 5 times or 2 times over vehicle microinjection-inducedBMC Biology 2006, 4:8 http://www.biomedcentral.com/1741-7007/4/8
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levels at equivalent point locations around drug vs. vehi-
cle microinjection tracks) (Figure 1).
Mapping procedure of microinjection plumes for 
localization of function
Cannulae used for behavioral tests after microinjections
were first located by measuring how far ventral ink
extended directly below a microinjection cannula, and
identifying the midway point on the vertical line between
the bottom of the cannula and the ventral edge of the ink
180° below. This center point was localized within a 0.1
mm margin of error and plotted on the coronal atlas page
that best fit that slice. The dorsal-ventral and medial-lat-
eral coordinates were read off the coronal atlas axes (+0.1
mm accuracy; [46] and the anterior-posterior coordinate
of the point was taken either from the coronal atlas page
(if the slice fit the page closely) or from the midpoint
between two adjacent atlas pages (if the slice appeared
intermediate between atlas sections; +0.2 mm accuracy).
Initial placements were made in the coronal plane
because the coronal plane has been most thoroughly
mapped in available standard atlases, and its greater
degree of detail facilitated more precise mapping of site
centers. The 3 coordinates of the center point were then
transformed into sagittal atlas locations to provide a sin-
gle simultaneous view of all microinjection sites in medial
shell of nucleus accumbens (accurate to 0.01 to 0.2 mm).
Coronal and horizontal maps were also constructed to
provide full 3-dimensional information on the location of
Fos plume spheres.
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